Widaplik is indicated for the treatment of hypertension, including as initial treatment, to lower blood pressure.

A final-stage clinical trial comparing a new long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects.

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for ...